CN101193638A - 用于良性前列腺肥大疗法的组合 - Google Patents

用于良性前列腺肥大疗法的组合 Download PDF

Info

Publication number
CN101193638A
CN101193638A CNA2006800207814A CN200680020781A CN101193638A CN 101193638 A CN101193638 A CN 101193638A CN A2006800207814 A CNA2006800207814 A CN A2006800207814A CN 200680020781 A CN200680020781 A CN 200680020781A CN 101193638 A CN101193638 A CN 101193638A
Authority
CN
China
Prior art keywords
inhibitor
pde
tablet
alpha
controlled release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2006800207814A
Other languages
English (en)
Chinese (zh)
Inventor
H·哈宁
P·瑟诺
E·比肖夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer Healthcare AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare AG filed Critical Bayer Healthcare AG
Publication of CN101193638A publication Critical patent/CN101193638A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
CNA2006800207814A 2005-04-13 2006-03-31 用于良性前列腺肥大疗法的组合 Pending CN101193638A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102005016981.3 2005-04-13
DE102005016981A DE102005016981A1 (de) 2005-04-13 2005-04-13 Kombination zur Therapie bei benigner Prostatahyperplasie

Publications (1)

Publication Number Publication Date
CN101193638A true CN101193638A (zh) 2008-06-04

Family

ID=36608700

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2006800207814A Pending CN101193638A (zh) 2005-04-13 2006-03-31 用于良性前列腺肥大疗法的组合

Country Status (22)

Country Link
EP (1) EP1888075A1 (pt)
JP (1) JP2008535877A (pt)
KR (1) KR20080007252A (pt)
CN (1) CN101193638A (pt)
AR (1) AR053575A1 (pt)
AU (1) AU2006233567A1 (pt)
BR (1) BRPI0610634A2 (pt)
CA (1) CA2605224A1 (pt)
CR (1) CR9427A (pt)
DE (1) DE102005016981A1 (pt)
DO (1) DOP2006000074A (pt)
GT (1) GT200600145A (pt)
IL (1) IL186604A0 (pt)
MA (1) MA29683B1 (pt)
MX (1) MX2007012567A (pt)
PE (1) PE20061338A1 (pt)
RU (1) RU2007141518A (pt)
SV (1) SV2008002477A (pt)
TN (1) TNSN07385A1 (pt)
TW (1) TW200716122A (pt)
UY (1) UY29473A1 (pt)
WO (1) WO2006108519A1 (pt)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102727456A (zh) * 2012-07-03 2012-10-17 北京科信必成医药科技发展有限公司 难溶性药物口腔崩解片及其制备方法
CN105338970A (zh) * 2013-06-28 2016-02-17 韩美药品株式会社 包含他达拉非和坦洛新的药物胶囊复合制剂
CN106659692A (zh) * 2014-06-30 2017-05-10 韩美药品株式会社 包括含有活性成分的膜包衣层的复合制剂
CN108066347A (zh) * 2016-11-16 2018-05-25 深圳万和制药有限公司 包含坦索罗辛和度他雄胺的口腔崩解片药物组合物
CN109843268A (zh) * 2016-10-25 2019-06-04 韩国爱技特药业株式会社 含度他雄胺和他达拉菲的速效复合片剂

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143746A (en) * 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
US20070093493A1 (en) * 2005-10-12 2007-04-26 Lilly Icos Llc Treatment of benign prostatic hypertrophy and lower urinary tract symptoms
US20080261995A1 (en) * 2005-12-21 2008-10-23 Pfizer Inc. Pharmaceutical Combination of a Pde-5 Inhibitor and a 5-Alpha Reductase Inhibitor
WO2008005039A1 (en) * 2006-07-07 2008-01-10 Teva Pharmaceutical Industries Ltd. Solid compositions comprising tadalafil and at least one carrier
DE102007028869A1 (de) 2007-06-22 2008-12-24 Ratiopharm Gmbh Verfahren zur Herstellung eines Arzneimittels enthaltend Tadalafil
NZ585923A (en) 2007-12-13 2012-09-28 Vanda Pharmaceuticals Inc Use of 4-[3-[4-(6-fluoro-1,2,-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxy-benzoic acid for treating a condition that is mediated by a 5-HT2A receptor
WO2009076663A1 (en) 2007-12-13 2009-06-18 Vanda Pharmaceuticals Inc. Method and composition for treating an alpha adrenoceptor-mediated condition
US8654746B2 (en) 2010-04-26 2014-02-18 Intel Corporation Method, apparatus and system for fast session transfer for multiple frequency band wireless communication
WO2013123965A1 (en) * 2012-02-20 2013-08-29 Synthon Bv A fixed dose pharmaceutical formulation
DK3024474T3 (da) 2013-07-23 2022-03-28 Serenity Pharmaceuticals Llc Sammensætninger omfattende desmopressin i kombination med en beta-3-adrenoreceptor-agonist
KR101663238B1 (ko) * 2013-11-15 2016-10-14 한미약품 주식회사 타다라필 및 암로디핀을 포함하는 복합 고형 제제
WO2016003181A1 (ko) * 2014-06-30 2016-01-07 한미약품 주식회사 활성성분-함유 필름 코팅층을 포함하는 복합제제
WO2016003180A1 (ko) * 2014-06-30 2016-01-07 한미약품 주식회사 5-α-환원효소 억제제-함유 필름 코팅층을 포함하는 복합제제 및 그 제조방법
KR20170097045A (ko) * 2014-11-20 2017-08-25 알레간 인코포레이티드 알파-아드레날린성 수용체 길항제와 조합된 데스모프레신을 포함하는 방법 및 조성물
JP2019510071A (ja) * 2016-03-31 2019-04-11 ハンミ ファーマシューティカルズ カンパニー リミテッド 安定性及び溶出率が改善されたタダラフィル含有及びタムスロシン含有のカプセル複合製剤
KR101879133B1 (ko) * 2017-07-11 2018-07-17 (주)동구바이오제약 비뇨기 질환 예방 또는 치료용 제제 및 이의 제조방법
TR201715231A2 (tr) * 2017-10-09 2019-04-22 Montero Gida Sanayi Ve Ticaret Anonim Sirketi Dapokseti̇n ve fosfodi̇esteraz ti̇p-5 i̇nhi̇bi̇törü i̇çeren farmasöti̇k kombi̇nasyon

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050042177A1 (en) * 2003-07-23 2005-02-24 Elan Pharma International Ltd. Novel compositions of sildenafil free base

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102727456A (zh) * 2012-07-03 2012-10-17 北京科信必成医药科技发展有限公司 难溶性药物口腔崩解片及其制备方法
CN102727456B (zh) * 2012-07-03 2016-06-22 北京科信必成医药科技发展有限公司 药物口腔崩解片及其制备方法
CN105338970A (zh) * 2013-06-28 2016-02-17 韩美药品株式会社 包含他达拉非和坦洛新的药物胶囊复合制剂
CN105338970B (zh) * 2013-06-28 2019-07-09 韩美药品株式会社 包含他达拉非和坦洛新的药物胶囊复合制剂
CN106659692A (zh) * 2014-06-30 2017-05-10 韩美药品株式会社 包括含有活性成分的膜包衣层的复合制剂
CN106659690A (zh) * 2014-06-30 2017-05-10 韩美药品株式会社 包括含有活性成分的膜包衣层的复合制剂
CN106659692B (zh) * 2014-06-30 2020-08-18 韩美药品株式会社 包括含有活性成分的膜包衣层的复合制剂
CN106659690B (zh) * 2014-06-30 2020-08-18 韩美药品株式会社 包括含有活性成分的膜包衣层的复合制剂
CN109843268A (zh) * 2016-10-25 2019-06-04 韩国爱技特药业株式会社 含度他雄胺和他达拉菲的速效复合片剂
CN109843268B (zh) * 2016-10-25 2021-12-14 韩国爱技特药业株式会社 含度他雄胺和他达拉菲的速效复合片剂
CN108066347A (zh) * 2016-11-16 2018-05-25 深圳万和制药有限公司 包含坦索罗辛和度他雄胺的口腔崩解片药物组合物

Also Published As

Publication number Publication date
AU2006233567A1 (en) 2006-10-19
DOP2006000074A (es) 2006-10-15
SV2008002477A (es) 2008-02-08
TNSN07385A1 (en) 2009-03-17
CR9427A (es) 2007-12-17
MA29683B1 (fr) 2008-08-01
UY29473A1 (es) 2006-11-30
CA2605224A1 (en) 2006-10-19
DE102005016981A1 (de) 2006-10-19
GT200600145A (es) 2007-04-10
JP2008535877A (ja) 2008-09-04
RU2007141518A (ru) 2009-05-20
KR20080007252A (ko) 2008-01-17
MX2007012567A (es) 2007-12-10
PE20061338A1 (es) 2007-01-28
IL186604A0 (en) 2008-01-20
EP1888075A1 (de) 2008-02-20
AR053575A1 (es) 2007-05-09
TW200716122A (en) 2007-05-01
WO2006108519A1 (de) 2006-10-19
BRPI0610634A2 (pt) 2010-07-13

Similar Documents

Publication Publication Date Title
CN101193638A (zh) 用于良性前列腺肥大疗法的组合
KR100364328B1 (ko) 알푸조신 염산염의 제어방출 정제
KR100618234B1 (ko) 다공성 입자를 포함하는 제형
CN103211779B (zh) 包含弱碱性选择性5-羟色胺5-ht3阻断剂和有机酸的药物递送系统
JP2638303B2 (ja) 異なる分子量を有するポリマー類を含んでなる投与形態
DK170110B1 (da) Farmaceutisk præparat med langsom frigivelse og anvendelse af fumarsyre til fremstilling af præpar atet
CA2616081C (en) Gastroretentive formulations and manufacturing process thereof
AU2008310735B2 (en) Methods of treating gastrointestinal disorders independent of the intake of food
CN101516351A (zh) 含有卡比多巴和左旋多巴的缓释固态药物组合物
US20070128276A1 (en) Controlled release compositions comprising nimesulide
US20090124702A1 (en) Pharmaceutical Compositions of Metformin
US20060099245A1 (en) Hydrodynamically balancing oral drug delivery system with biphasic release
KR20090065524A (ko) 프로그래머블 부력전달기술
CN101785769A (zh) 包含替米沙坦的固体药用制剂
RU2580652C2 (ru) Фармацевтическая композиция для орального введения
CN108201536A (zh) 一种奥拉帕尼口服缓控释药物组合物及其用途
CN101287452A (zh) 包含1-（4-氯苯胺基）-4-（4-吡啶基甲基）-2,3-二氮杂萘和pH调节剂的固体药物组合物
MXPA05004410A (es) Composiciones de liberacion controlada.
CN108201534A (zh) 一种瑞卡帕布口服缓控释药物组合物及其用途
AU2004205184A1 (en) Sustained/controlled release solid formulation as a novel drug delivery system with reduced risk of dose dumping
Zahirul Khan Recent trends and progress in sustained or controlled oral delivery of some water soluble drugs: morphine salts, diltiazem and captopril
US20120003307A1 (en) Levetiracetam controlled release composition
CN110035751A (zh) 一种维利帕尼缓控释药物组合物及其用途
CN101217943B (zh) 药物活性组分的缓释剂型
KR20040047920A (ko) 피페라진 우레아 유도체를 위한 고체 제약 제제

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1123485

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20080604

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1123485

Country of ref document: HK